What Schools Are Affiliated With Roy S. Herbst

Roy S. Herbst is affiliated with the following schools: Emory University, Indiana University, MD Anderson Cancer Center, University of Oxford, Weill Cornell Medicine, Tongji University, University of Toronto, Indiana University Bloomington, Yale University, Kobe University, University of Arizona, University of Colorado Denver, Vanderbilt University, China Medical University , Rockefeller University, University of Colorado, Shanghai Jiao Tong University, Rush University, Fudan University, University of Texas Southwestern Medical Center, University of Pennsylvania, Harvard University, Heidelberg University

Roy S. Herbst | Academic Influence

Roy S. Herbst's AcademicInfluence.com Rankings

Roy S. Herbst

Medical

#394

World Rank

#551

Historical Rank

Oncology

#19

World Rank

#20

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Roy S. Herbst Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

(See a Problem?)

Roy S. Herbst's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2016) (4871)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (2014) (4187)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003) (2609)
The biology and management of non-small cell lung cancer (2018) (2193)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. (2004) (1937)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (2004) (1790)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004) (1779)
Lung cancer. (2008) (1699)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005) (1538)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. (2005) (1488)
Longitudinal analyses reveal immunological misfiring in severe COVID-19 (2020) (1431)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
Review of epidermal growth factor receptor biology. (2004) (1259)
The BATTLE trial: personalizing therapy for lung cancer. (2011) (810)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. (2016) (781)
Programmed death ligand-1 expression in non-small cell lung cancer (2014) (707)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. (2016) (688)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer (2007) (604)
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. (2020) (590)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. (2020) (587)
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. (2002) (581)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. (2005) (533)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. (2002) (516)
The proteasome inhibitor PS-341 in cancer therapy. (1999) (493)
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors (2002) (485)
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. (2005) (469)
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. (2003) (464)
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (2018) (445)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. (2010) (418)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. (2007) (415)
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. (2012) (413)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. (2017) (397)
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. (2010) (390)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (2011) (380)
Gefitinib — a novel targeted approach to treating cancer (2004) (354)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis (2017) (342)
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. (2014) (334)
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy (2019) (334)
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes (2019) (330)
To kill a tumor cell: the potential of proapoptotic receptor agonists. (2008) (325)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. (2005) (313)
Objective measurement and clinical significance of TILs in non-small cell lung cancer. (2015) (309)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. (2008) (300)
Phase I study of recombinant human endostatin in patients with advanced solid tumors. (2002) (292)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. (2007) (283)
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. (2005) (281)
Epidermal growth factor receptor biology (IMC-C225) (2001) (267)
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. (2005) (258)
Angiogenesis and lung cancer: prognostic and therapeutic implications. (2005) (253)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA (2018) (243)
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (2009) (241)
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. (2002) (234)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. (2020) (221)
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. (2003) (220)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. (2008) (216)
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. (2000) (214)
Immunotherapy in Lung Cancer. (2017) (210)
Mode of action of docetaxel - a basis for combination with novel anticancer agents. (2003) (209)
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. (2003) (208)
Scientific Advances in Lung Cancer 2015 (2016) (207)
Tyrosine hydroxylase-immunoreactive neurons of the hypothalamus: A light and electron microscopic study (1984) (203)
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. (2013) (203)
Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine (2008) (200)
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. (2002) (193)
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. (2007) (187)
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies (2008) (181)
Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement (2013) (181)
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). (2004) (179)
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. (2016) (174)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. (2006) (173)
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. (2004) (166)
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. (2003) (165)
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer (2001) (163)
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors (2012) (160)
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. (2011) (160)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies (2010) (156)
Methodological and practical challenges for personalized cancer therapies (2011) (156)
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. (2000) (155)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. (2019) (153)
Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. (2000) (151)
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. (2011) (151)
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. (2005) (150)
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo (2010) (148)
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis (2007) (148)
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. (2005) (148)
Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients (2013) (146)
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis (2019) (144)
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy (2019) (143)
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells (2019) (141)
Toward personalized treatment approaches for non-small-cell lung cancer (2021) (141)
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer (2004) (141)
Lung Cancer in the Era of Precision Medicine (2015) (138)
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. (2013) (137)
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. (2018) (132)
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. (2020) (130)
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer (2004) (129)
Targeting the epidermal growth factor receptor in non-small cell lung cancer. (2003) (129)
Immuno-thermal ablations – boosting the anticancer immune response (2017) (128)
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (126)
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer (2016) (125)
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. (2016) (124)
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery (2017) (124)
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. (2015) (123)
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors (2010) (122)
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. (2016) (121)
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. (2005) (121)
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC (2019) (121)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer (2017) (121)
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. (2015) (117)
Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. (2013) (117)
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) (2018) (116)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers (2018) (116)
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. (2000) (116)
Dermatologic side effects associated with gefitinib therapy: clinical experience and management. (2003) (115)
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. (2001) (114)
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. (2010) (113)
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. (2004) (112)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (110)
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (108)
Emerging therapies in non-small-cell lung cancer. (2001) (102)
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer (2007) (100)
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. (2002) (99)
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow (2008) (98)
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting (2018) (97)
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. (2006) (96)
Erlotinib (Tarceva): an update on the clinical trial program. (2003) (95)
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC (2021) (95)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (2013) (94)
Small-cell lung cancer: prognostic factors and changing treatment over 15 years. (2012) (93)
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer (2006) (92)
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. (2020) (92)
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (2017) (91)
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer (2005) (91)
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes (2017) (90)
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade (2007) (90)
Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. (2005) (90)
A phase I surrogate endpoint study of SU6668 in patients with solid tumors (2004) (89)
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (2015) (89)
Surrogate markers in antiangiogenesis clinical trials (2003) (87)
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer (2009) (86)
Smoking cessation, version 1.2016 clinical practice guidelines in oncology (2016) (85)
Integration of Molecular Profiling into the Lung Cancer Clinic (2009) (85)
A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung (2010) (84)
Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology (2015) (84)
Positive and negative regulatory elements in the mouse albumin enhancer. (1989) (84)
Guillain-Barré syndrome following allogeneic bone marrow transplantation (1997) (83)
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) (2019) (81)
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors (2004) (79)
Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials (2019) (78)
Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways (2006) (78)
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer (2014) (78)
Treatment of Advanced Non-Small Cell Lung Cancer in 2018. (2018) (77)
Therapeutic options to target angiogenesis in human malignancies (2006) (76)
Molecular signatures of lung cancer--toward personalized therapy. (2007) (76)
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells (2013) (75)
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function (2016) (75)
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models (1998) (75)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up (2017) (73)
E2F8 as a Novel Therapeutic Target for Lung Cancer. (2015) (72)
Clinical Features and Management of Acquired Resistance to PD‐1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer (2018) (71)
A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. (2006) (70)
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. (2005) (70)
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. (2020) (70)
ADAURA: Phase III, Double‐blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation‐positive Early‐stage NSCLC After Complete Surgical Resection (2018) (70)
Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. (2015) (69)
ZD1839: targeting the epidermal growth factor receptor in cancer therapy (2002) (68)
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) (2000) (68)
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor (2010) (67)
Lung cancer in patients under age 40. (2001) (67)
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction (2014) (67)
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? (2004) (66)
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. (2003) (66)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). (2009) (66)
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 (2019) (65)
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. (2010) (65)
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. (2002) (65)
Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide) (2004) (65)
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. (2004) (64)
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. (2010) (64)
Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer (2008) (64)
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. (2008) (63)
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. (2011) (62)
Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types. (1987) (62)
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. (2021) (62)
Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research (2016) (60)
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer (2016) (60)
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. (2017) (60)
Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. (1998) (59)
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma (2013) (59)
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. (2021) (58)
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. (2018) (58)
Treatment with HIF-1&agr; Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice (2010) (58)
“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation (2014) (57)
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. (2004) (57)
A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. (2021) (57)
Tobacco and cancer: an American Association for Cancer Research policy statement. (2010) (56)
A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342 (2007) (56)
Immune checkpoint therapy for non-small-cell lung cancer: an update. (2016) (56)
Novel therapeutics for head and neck cancer (2002) (56)
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial (2013) (55)
ZD1839 (Iressa) in non-small-cell lung cancer. (2002) (55)
Immune Checkpoint Inhibitor-Associated Pericarditis. (2019) (53)
Opening Up to Precompetitive Collaboration (2010) (53)
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial (2019) (53)
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. (2002) (53)
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. (2010) (53)
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis (2012) (52)
Angiogenesis inhibitors in clinical development for lung cancer. (2002) (52)
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. (2003) (52)
The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein (1990) (51)
Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. (2012) (51)
Angiogenesis and lung cancer: potential for therapy. (2000) (50)
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. (2008) (50)
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck (2001) (50)
Toxicities of antiangiogenic therapy in non-small-cell lung cancer. (2006) (50)
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer (2017) (50)
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin (2001) (49)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2017) (49)
Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials (2007) (49)
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer (2017) (48)
Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin (1997) (48)
Assessment of antiangiogenic effect using 99mTc-EC-endostatin. (2002) (47)
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice (2007) (47)
Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor (2006) (47)
Current management of advanced non-small cell lung cancer: targeted therapy. (2005) (47)
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist (2012) (46)
Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC (2005) (46)
Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 (2012) (46)
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling (2020) (46)
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities (2022) (46)
Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases. (2017) (46)
First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors (2007) (45)
Health‐Related Quality of Life in KEYNOTE‐010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC (2019) (45)
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. (2007) (44)
Prostate carcinoma response to cytotoxic therapy: in vivo resistance. (1997) (44)
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies (2015) (43)
Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (43)
Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA) (2007) (43)
Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. (1997) (43)
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours (2011) (43)
Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). (2019) (43)
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. (2016) (43)
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition (2006) (43)
Use of novel second-line targeted therapies in non-small cell lung cancer. (2006) (42)
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. (2005) (41)
Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials (2012) (41)
Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. (2015) (41)
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. (2019) (41)
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors (2004) (40)
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. (2004) (40)
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors (2005) (40)
Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study). (2019) (40)
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC (2005) (40)
A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer (2007) (40)
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer (2022) (38)
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (38)
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. (2018) (38)
Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. (2006) (38)
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer. (2021) (37)
Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer. (2019) (37)
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. (2004) (37)
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer (2014) (37)
Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). (2019) (36)
Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. (1991) (36)
Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. (2010) (36)
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. (2002) (36)
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer (2009) (36)
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors (2004) (35)
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma (2002) (35)
Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer (2007) (35)
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. (2018) (34)
Frontline immunotherapy for NSCLC — the tale of the tail (2020) (34)
EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer. (2015) (34)
Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro (2018) (33)
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs (2014) (33)
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors (2011) (33)
Targeted drug delivery strategies to treat lung metastasis (2009) (33)
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}. (2010) (32)
S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. (2009) (31)
ZD1839 (Iressa) in non-small cell lung cancer. (2001) (31)
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway – Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) (2019) (31)
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. (2010) (31)
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. (2019) (31)
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (31)
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. (2002) (31)
Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen (2009) (31)
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. (2006) (30)
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial (2001) (30)
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. (1997) (30)
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research (2016) (30)
Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. (2006) (30)
Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer (2000) (30)
Longitudinal analyses reveal immunological misfiring in severe COVID-19 (2020) (30)
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. (2020) (29)
Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC) (2000) (29)
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice (2020) (29)
Lung-MAP--framework, overview, and design principles. (2015) (29)
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer (2021) (29)
Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection (2020) (28)
Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 (2019) (28)
Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. (2009) (28)
Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety (2000) (28)
Acute in vivo resistance in high-dose therapy. (1998) (26)
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). (2018) (26)
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. (2016) (26)
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. (2004) (26)
KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. (2009) (26)
ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. (2022) (26)
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours (2012) (26)
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). (2020) (25)
Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). (2017) (25)
Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (2018) (25)
Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients (2020) (25)
Lung Endothelial MicroRNA‐1 Regulates Tumor Growth and Angiogenesis (2017) (25)
A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. (2014) (25)
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial (2005) (25)
A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. (2017) (25)
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab (2017) (24)
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours (2012) (24)
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy (2004) (24)
Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists (2009) (24)
Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography: A Comparison Study (2009) (24)
Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer (2013) (24)
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development (2016) (23)
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536 (2013) (23)
Tumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation (2018) (23)
Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials (2005) (23)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). (2009) (23)
Gefitinib: current and future status in cancer therapy. (2003) (22)
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. (2010) (22)
A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress (2015) (22)
Molecular origins of lung cancer: prospects for personalized prevention and therapy. (2010) (22)
Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors (2007) (22)
Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. (2001) (22)
Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer (2008) (21)
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. (2009) (21)
Angiogenesis inhibition in the treatment of lung cancer. (2006) (21)
Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial (2012) (21)
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. (2010) (21)
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) (2011) (21)
Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. (2007) (21)
ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. (2004) (21)
Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study. (2006) (21)
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer (2015) (20)
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. (2006) (20)
Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. (2014) (20)
Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial (2001) (19)
Phase I participants’ views of quality of life and trial participation burdens (2007) (19)
Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. (2017) (19)
Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). (2014) (19)
Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. (2002) (19)
The changing face of Phase 1 cancer clinical trials (2009) (19)
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
“Companion Diagnostics”: Has Their Time Come and Gone? (2014) (18)
The role of growth factor signaling in malignancy. (2003) (18)
Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer (2011) (18)
Angiogenesis as a target for cancer therapy. (2002) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. (2013) (18)
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 (2021) (18)
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial (2013) (18)
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. (2012) (18)
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. (2011) (18)
Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials (2008) (18)
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. (1999) (17)
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD 8 T Cells Graphical (2019) (17)
GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer (2016) (17)
Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. (2009) (17)
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer (2003) (17)
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. (2004) (17)
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer (2014) (17)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. (2009) (16)
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer. (2020) (16)
Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. (2016) (16)
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. (2017) (16)
A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). (2004) (16)
Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors (2004) (16)
Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling (2010) (15)
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial (2020) (15)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer (2004) (15)
Small molecule combats cancer-causing KRAS protein at last (2019) (15)
Diminished but not dead: chemotherapy for the treatment of NSCLC. (2016) (15)
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. (2016) (15)
Targeted therapy in non-small-cell lung cancer. (2002) (15)
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC. (2016) (15)
P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study (2005) (15)
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. (2003) (14)
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. (2016) (14)
Role of novel targeted therapies in the clinic (2005) (14)
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN) (2007) (14)
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (2022) (14)
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A (2022) (14)
LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC (2021) (14)
Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. (2009) (14)
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. (2017) (14)
Chemotherapy for advanced non-small cell lung cancer. (1997) (14)
An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer (2011) (14)
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). (2013) (14)
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021) (13)
Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection (2021) (13)
The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function (1990) (13)
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. (2009) (13)
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck (2009) (13)
ZD1839 (IressaTM) in Non-Small Cell Lung Cancer (2002) (13)
A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. (2017) (13)
83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A (2017) (13)
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. (2006) (13)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2018) (13)
Antiangiogenic tumor therapy. (2003) (13)
The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. (2002) (13)
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC (2008) (13)
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting (2017) (13)
Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC) (2007) (13)
Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC (2016) (12)
The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. (2003) (12)
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib (2015) (12)
ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer (2004) (12)
First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors (2007) (12)
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy (2009) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene (2005) (12)
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). (2019) (12)
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. (2016) (11)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects (2022) (11)
90PDPreviously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data (2017) (11)
Regulation of adenovirus and cellular gene expression and of cellular transformation by the E1B-encoded 175-amino-acid protein (1988) (11)
Personalized therapy. (2012) (11)
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy (2009) (11)
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. (2014) (11)
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly (2004) (11)
A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. (2017) (11)
Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. (2010) (10)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". (2008) (10)
Erratum: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up [Ann Oncol, 28, 1, (2017) (75-82)] DOI: 10.1093/annonc/mdw436 (2017) (10)
151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors (2004) (10)
Angiogenesis inhibitors in lung cancer (2002) (10)
Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P) (2016) (10)
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 (2016) (10)
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer (2003) (10)
LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence (2020) (9)
1313P Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC (2020) (9)
Imaging in drug development. (2004) (9)
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response (2005) (9)
Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. (2019) (9)
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression (2021) (9)
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer (2019) (9)
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer (2018) (9)
Angiogenesis, metastasis, and lung cancer. An overview. (2003) (9)
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. (2016) (9)
A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC) (2007) (9)
EGFR tyrosine kinase inhibitors in squamous cell lung cancer. (2015) (9)
Challenges and approaches to implementing master/basket trials in oncology. (2019) (9)
Bad Blood: A Case Study of the Tuskegee Syphilis (1994) (8)
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. (2016) (8)
Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. (2012) (8)
Lisofylline as a modifier of radiation therapy. (1996) (8)
Angiogenesis and lung cancer: implications for prognosis and treatment. (2007) (8)
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. (2017) (8)
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD‐L1–Selected Chemotherapy‐Naive NSCLC Patients: Topic: Medical Oncology (2016) (8)
Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). (2016) (8)
Multitargeted inhibitors in lung cancer: new clinical data. (2008) (8)
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. (2016) (8)
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study (2019) (8)
A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) (2000) (7)
Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. (2013) (7)
Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. (2017) (7)
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC (2020) (7)
Pemetrexed in advanced NSCLC: a review of the clinical data. (2004) (7)
Spotlight on Clinical Response Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo 2 L / TRAIL ( Dulanermin ) , a Dual Proapoptotic Receptor ( DR 4 / DR 5 ) Agonist (2012) (7)
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). (2020) (7)
A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). (2019) (7)
A step towards treating KRAS-mutant NSCLC. (2013) (7)
Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons. (2021) (7)
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. (2004) (7)
Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. (2004) (7)
MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC) (2005) (7)
Enzastaurin , a Protein Kinase C B ^ Selective Inhibitor , and Its PotentialApplicationasanAnticancer AgentinLungCancer (2007) (6)
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC (2021) (6)
Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. (2009) (6)
O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy (2005) (6)
Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men? (2008) (6)
Adversarial Attack Vulnerability of Deep Learning Models for Oncologic Images (2021) (6)
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). (2019) (6)
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. (2014) (6)
Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment (2004) (6)
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer (2022) (6)
Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer? (2018) (6)
The KRAS-variant and treatment response in BATTLE-1. (2014) (6)
Angiogenesis inhibition and lung-cancer therapy. (2014) (6)
Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancer. (2000) (6)
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC (2021) (6)
Molecular targeted therapy for lung cancer (2005) (6)
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. (2021) (6)
Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside". (2019) (6)
Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. (2017) (5)
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. (2020) (5)
P-522 A phase II trial of Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) (2003) (5)
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma (2018) (5)
FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC (2021) (5)
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. (1997) (5)
Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC). (2006) (5)
Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors (2008) (5)
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions (2021) (5)
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006. (2019) (5)
OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D (2017) (5)
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. (2008) (5)
Management of Advanced Non–Small Cell Lung Cancer (2018) (5)
Antiangiogenic Cancer Therapy (2007) (5)
Clinician Perspectives on Current Issues in Lung Cancer Drug Development (2016) (5)
Patient selection criteria and the FLEX Study (2009) (5)
Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma (2008) (5)
LBA3_PRKEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy (2015) (5)
Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer Centers (2014) (5)
SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). (2009) (5)
MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) (2019) (5)
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. (2018) (5)
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial (2022) (5)
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (2011) (5)
Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). (2022) (4)
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. (2022) (4)
355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC (2015) (4)
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. (2022) (4)
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. (2005) (4)
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. (2016) (4)
Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection (2019) (4)
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303) (2007) (4)
New targets for the treatment of advanced non-small cell lung cancer. (2002) (4)
MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) (2017) (4)
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). (2016) (4)
Managing cutaneous side effects associated with erlotinib in head and neck cancer (HNC) and non-small cell lung cancer (NSCLC) patients (pts). (2006) (4)
Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC) (2015) (4)
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). (2014) (4)
ZD1839 (Iressa TM ) In Non-Small-Cell Lung Cancer (2001) (4)
DRAFT FOR PUBLIC COMMENT Defining Clinically Meaningful Outcomes: ASCO Recommendations to Raise the Bar for Clinical Trials (2013) (4)
Miscellaneous agents. (2012) (4)
Molecular events surrounding the angiogenic switch of lung cancer (2012) (4)
Targeting the epidermal growth factor receptor: prognostic and clinical implications (2003) (4)
Development of an Immunohistochemical Assay for Siglec-15 (2022) (4)
A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases (2017) (4)
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. (2021) (3)
Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology (2009) (3)
O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer (2003) (3)
Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies (2008) (3)
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. (2018) (3)
Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. (2018) (3)
When immunotherapy meets surgery in non-small cell lung cancer. (2022) (3)
SWOG-S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) (2010) (3)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. (2020) (3)
OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC (2021) (3)
Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. (2019) (3)
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer (2022) (3)
KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) (2019) (3)
P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC: Topic: IT (2017) (3)
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (2023) (3)
Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). (2012) (3)
Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. (2015) (3)
AZD2171, an oral, highly potent VEGFR signaling inhibitor, in combination with gefitinib or paclitaxel: Results of a study in an orthotopic human lung adenocarcinoma model. (2005) (3)
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). (2020) (3)
Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. (2020) (3)
Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (2008) (3)
EGFR inhibition in NSCLC: the emerging role of cetuximab. (2004) (3)
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) (2016) (3)
Surgery: Future directions in multimodality therapy for NSCLC (2010) (3)
Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition (2001) (3)
MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC (2019) (3)
Integration of targeted therapies in gemcitabine chemotherapy regimens. (2003) (3)
Treated PI 3 K-Positive Patients with Stage IV Squamous Cell Lung Cancer ( Lung-MAP Sub-Study ) (2019) (3)
52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib (2003) (3)
15PDIn patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers (2017) (2)
Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. (2022) (2)
PD-044 Optimal treatment for superior sulcus tumors (SST): Surgery first followed by adjunct RT/ChT improved survival for patients with resectable SST (2005) (2)
B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC) (2007) (2)
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. (2020) (2)
Abstract PR03: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. (2014) (2)
Tyrosine-kinase inhibitors in oncology (2015) (2)
Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. (2016) (2)
personalized medicine Bayesian adaptive design for targeted therapy development in lung cancera step toward (2010) (2)
Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. (2017) (2)
143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC (2017) (2)
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC. (2022) (2)
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. (2022) (2)
PS01.62: Long‐Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology (2016) (2)
Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry (2017) (2)
Erratum: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers (Science Translational Medicine DOI: 10.1126/scitranslmed.aao4307) (2019) (2)
Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC). (2016) (2)
The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. (2014) (2)
Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers. (2013) (2)
VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab (2008) (2)
Using Adversarial Images to Assess the Stability of Deep Learning Models Trained on Diagnostic Images in Oncology (2021) (2)
Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP) (2005) (2)
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. (2021) (2)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
Advances in Treatment of Non–Small-Cell Lung Cancer (2003) (2)
Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes (2019) (2)
A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). (2021) (2)
P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model: Topic: IT Biomarkers (2017) (2)
MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis (2021) (2)
O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy (2003) (2)
Osimertinib in EGFR-Mutated Lung Cancer. Reply. (2021) (2)
Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer (2005) (2)
P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (2019) (2)
Angiogenesis pathway inhibitors. (2005) (2)
Targeting PD1 and PDL1 in lung cancer treatment: Where are we now? (2016) (2)
Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trials (2012) (2)
1341PAssessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA (2017) (2)
A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine (2007) (1)
P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas: Topic: Translational Research and Biomarkers (2017) (1)
Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. (2014) (1)
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. (2022) (1)
Positive and negative regulatory elements in the mouse albumin enhancer ( tissue-specific gene expression / transcription factors / negative regulation (1)
Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (2011) (1)
A phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (1)
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) (2021) (1)
Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma (2016) (1)
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer (2011) (1)
P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (2019) (1)
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study. (2019) (1)
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. (2020) (1)
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534) (2009) (1)
AJ-2Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer Therapies (2015) (1)
Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. (2017) (1)
HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. (2016) (1)
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer (2019) (1)
Who should go first in trials with scarce agents? The views of potential participants. (2007) (1)
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). (2013) (1)
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). (2018) (1)
Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung Cancer. (2011) (1)
How a Priority of Community Outreach and Engagement Is Changing Health Equity at Cancer Centers (2021) (1)
Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer (2016) (1)
Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC) (2012) (1)
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. (2022) (1)
Limited small cell lung cancer (stages I-III): Observations from the National Cancer Database. (2004) (1)
Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma model (2010) (1)
Treatment of Advanced Non-Small Cell Lung Cancer: Second-line Therapy With Novel Agents (2008) (1)
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). (2004) (1)
Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. (2022) (1)
Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancer (2021) (1)
Current and future strategies for antiangiogenic agents in non-small-cell lung cancer. (2008) (1)
Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors (2018) (1)
366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase (2010) (1)
Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply. (2021) (1)
Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone (2008) (1)
Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). (2017) (1)
Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer (2022) (1)
MS-4 Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial (2004) (1)
PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program (2007) (1)
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. (2018) (1)
BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis (2019) (1)
ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature (2005) (1)
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. (2016) (1)
103 POSTER A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC) (2006) (1)
The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53 -Driven Lung Cancer (2019) (1)
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (2009) (1)
Abstract C115: Yale Cancer Disparities Firewall Project: Taking lifestyle change and cancer screening into the community to reduce cancer disparities (2020) (1)
MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates (2017) (1)
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). (2009) (1)
Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer (2020) (1)
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer (2022) (1)
Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma. (2014) (1)
Systemic chemotherapy as a primary treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) (2000) (1)
Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial (2013) (0)
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. (2022) (0)
Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology (2010) (0)
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents (2008) (0)
A phase I clinical trial of recombinant human endostatin in patients with solid tumors Surrogate analyses to determine a biologically effective dose (2001) (0)
Abstract B045: Operationalizing community engagement and participation: Experiences of the Yale Cancer Disparities Firewall Project to impact lifestyle change and cancer screening (2020) (0)
Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models (2007) (0)
Targeted therapy against VEGFR-1, -2, and -3 by AZD2171 blocks tumor growth and angiogenesis, and enhances paclitaxel efficacy in an orthotopic lung cancer model (2007) (0)
Alimta/Platinum Doublets Studied for Palliative Care of Advanced NSCLC (2005) (0)
II. Business (Approvals) (2011) (0)
4-18-2017 The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31 st anniversary annual meeting Howard (2018) (0)
Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients (2007) (0)
Immune Checkpoint Inhibition in Lung Cancer (2018) (0)
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). (2021) (0)
Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). (2018) (0)
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). (2020) (0)
Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I. (2023) (0)
Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients. (2014) (0)
Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models (2014) (0)
Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer. (2002)95(2):340–353. (2003) (0)
157 : Limited Small Cell Lung Cancer (LSCLC) - Observations From The National Cancer Database on the Impact of Age, Gender and Treatment on Survival (2006) (0)
2659 : Inhibition of VEGFR-1, -2, and -3 Signaling by AZD2171 Enhances the Anti-Tumor Efficacy of Radiation Therapy in a Mouse Xenograft Model (2006) (0)
P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era (2021) (0)
I. SUBJECT: NEW PRINCIPAL INVESTIGATORS (PI) AND CO-PI Recommendations have been made that the following physicians assume the responsibilities of Principal Investigators and Co-Principal Investigators at the following Member and CCOP Institutions: (2011) (0)
Abstract 2580: Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and Ipilimumab for previously treated patients with stage IV squamous cell lung cancer: an immune biomarker analysis of Phase III SWOG LungMAP S1400I trial (2022) (0)
What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? (2005) (0)
Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab. (2022) (0)
Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis (2011) (0)
OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A (2021) (0)
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab (2022) (0)
Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial. (2020) (0)
MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool (2017) (0)
Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model. (2013) (0)
inhibition independent urokinase-type plasminogen activator − factor protein-3 in lung cancer is mediated by insulin-like growth Antimetastatic activity of insulin-like growth factor binding (2006) (0)
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
How to Promote and Organize Clinical Research in Lung Cancer (2018) (0)
O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response (2003) (0)
Image Guidance of Screening, Staging and Combined Modality Management of Non–Small Cell Lung Cancer (2007) (0)
O-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer (2003) (0)
Abstract C118: Utilizing health navigators and technology to increase cancer screening and healthy lifestyle: Preliminary findings from the Yale Cancer Disparities Firewall Project (2020) (0)
Abstracts From: The 10th International Lung Cancer Congress June 17–20, 2009; Kohala Coast, HI (2009) (0)
ESMO-ASCO joint symposium: the evolution of the clinical trials landscape (2014) (0)
DesignofaPhaseIIIClinicalTrialwithProspectiveBiomarker Validation: SWOG S0819 (2012) (0)
Investigators Seek Markers for Sensitivity to EGFR Inhibitors (2005) (0)
Nonplatinum Doublet Vinorelbine/ Gemcitabine Effective in NSCLC (2003) (0)
Encouraging Clinical Experience With Erlotinib in Lung Cancer (2003) (0)
Highlights from: The 13th world conference on lung cancer (2009) (0)
Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. (2012) (0)
The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy (2010) (0)
Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer (2018) (0)
Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program (2010) (0)
111 POSTER A dose escalation study of AMG 386, a selective inhibitor of angiopoietin-2, in adult patients with advanced solid tumors (2006) (0)
Abstract PO-263: COVID-19 and social determinants of health (SDOH): Impact on cancer prevention in vulnerable populations (2020) (0)
Abstract 3938: Role of Chi3l1/YKL-40 in the tumor progression and metastasis in the lung. (2013) (0)
Cetuximab/Docetaxel Combination Shows Promise Against Advanced Non–Small-Cell Lung Cancer (2003) (0)
FDA Approves Alimta as Second-Line Tx (2005) (0)
Radiofrequency Ablation Complements Radiation in Patients With Unresectable Early NSCLC (2005) (0)
Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma (2011) (0)
SC14.01 Immunotherapy in the First-Line Setting of Advanced NSCLC (2017) (0)
Abstract 1051: EGFR inhibitors attenuate caspase-independent cell death and confer negative effects on cisplatin . (2013) (0)
Newer Combination Therapies and Targets Reported for Advanced NSCLC (2003) (0)
Future directions of monoclonal antibody use in personalized lung cancer therapy. (2010) (0)
With Cetuximab and Erlotinib, Rash Correlates With Survival (2003) (0)
P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer (2021) (0)
Assessing the Ethics of Ethics Research: A Case Study (2004) (0)
Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative (2020) (0)
Adjuvant Chemo Might Prevent 7,000 NSCLC Deaths Worldwide Each Year (2003) (0)
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study. (2018) (0)
119INNOVEL MOLECULAR STUDIES TO INFORM THE CONDUCT OF ONCOLOGY CLINICAL TRIALS: FROM BATTLE TO MASTER PROTOCOLS. (2014) (0)
Title Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma (2015) (0)
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress (2022) (0)
Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer (2022) (0)
781 The prognosis of lung cancer in patients (pts) under age 40 (1997) (0)
P3-164: A phase II trial of pemetrexed(p) in patients (pts) with performance status (PS) 2 and 3 as 1st– and 2nd– line treatment for advanced non–small–cell lung cancer (NSCLC) (2007) (0)
Early Data Indicate Erlotinib Controls Advanced NSCLC in Elderly Patients, Phase II Trial Shows (2005) (0)
Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series: Targeting VEGF - Current and future research directions (2005) (0)
FDA Urged to Add Endpoints for Approving NSCLC Drugs (2005) (0)
Abstract PO-082: Relationships between social determinants of health and cancer prevention navigation program outcomes in the Yale Cancer Disparities Firewall Project (2020) (0)
Addition of thalidomide to chemotherapy does not improve efficacy of carboplatin/etoposide in small-cell lung cancer: Phase III results (2007) (0)
The changing face of phase I protocols: A closer look at study requirements (2007) (0)
In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor. (2003) (0)
Abstract 5605:LKB1andKRASmutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer (2012) (0)
Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging (2023) (0)
Vascular endothelial growth factor trap in non-small cell lung cancer. Discussion (2007) (0)
392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib (2008) (0)
Lung Cancer Management: Emerging Strategies (2005) (0)
The Evolving Role of Biomarkers to Enhance Personalized Medicine (2018) (0)
ISY8-3Personalized immunotherapy for advanced non-small cell lung cancer (2015) (0)
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. (2020) (0)
Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer (2015) (0)
Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor (2009) (0)
Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC) (2017) (0)
PET/CT Outperforms PET or CT Alone in Imaging Non–Small-Cell Lung Cancer (2005) (0)
ゲフィチニブ（イレッサ®）の非盲検多施設国際共同による長期継続投与試験 (2006) (0)
Cancer Therapy: Preclinical Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells (2013) (0)
NIH Institutes Fund Seven New Tobacco Research Centers (2005) (0)
Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment. (2004) (0)
Microenvironment and Immunology CXCR 2 Expression inTumorCells Is aPoorPrognosticFactor and Promotes Invasion and Metastasis in Lung Adenocarcinoma (2013) (0)
Master Protocol Multi-drug Registration Trial Design Proposal (0)
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer (2023) (0)
Co-Option of the Extracellular Matrix During Lung Cancer Metastasis and Therapeutic Repsonse (2017) (0)
Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma (2016) (0)
Clinical Targeting of VEGF and EGFR Effective in Non-Small Cell Lung Cancer (2004) (0)
Handbook of Advanced Cancer Care: Head and neck cancer (2003) (0)
Congress Denies FDA Power to Regulate Tobacco Products (2005) (0)
Production of malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells (2000) (0)
How the Treatment of Lung Cancer Has Been Transformed in the Era of Molecular Biomarker Testing (2018) (0)
Iressa Approved for Advanced NSCLC (2003) (0)
Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC) (2015) (0)
Computer Aided Detection Helps Radiologists Find Lung Nodules (2005) (0)
Immunotherapeutic Approaches to the Treatment of Squamous Non-Small Cell Lung Cancer (2015) (0)
Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial (2022) (0)
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies (2015) (0)
Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial. (2016) (0)
S4-4 Integration of Correlative Science into Clinical trial Design in Lung Cancer (2004) (0)
Introduction by the Guest Editors. (2020) (0)
Inhalation Therapy for Lung Cancer ‘Primed for Growth,’ Investigator Says (2005) (0)
Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time Periods (2011) (0)
Multidisciplinary Approach Improves Staging of NSCLC (2003) (0)
NCI Addresses Tobacco- Related Cancers in Women (2005) (0)
Docetaxel–HER1/EGFR Drug Combo Is Promising in Recurrent NSCLC (2003) (0)
Targeting protein kinase C beta enhances cell death of non-small cell lung cancer cells. (2006) (0)
New TNM staging guidelines for non-small-cell lung cancer (2007) (0)
Abstract S03-03: Cancer patients display diminished viral RNA clearance and altered T cell responses during SARS-CoV-2 infection (2021) (0)
The Evolving Role of PD-L1 Testing in Patients with Cancer (2018) (0)
Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial (2020) (0)
Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition (2002) (0)
Current Therapeutic Strategies in Non–Small-Cell Lung Cancer: Evolving Roleof Docetaxel (2005) (0)
Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models (2007) (0)
Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC (2014) (0)
IS7–2PERSONALIZED THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: FROM THE BATTLE TRIAL TO MASTER PROTOCOLS (2013) (0)
Evolving Treatment Options for Lung Cancer. (2017) (0)
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). (2022) (0)
Advances and Opportunities in the Management of Lung Cancer. (2023) (0)
MS21.06 Immunotherapy - Sequence or Combination? (2018) (0)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (0)
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. (2023) (0)
Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC) (2017) (0)
Protein Kinase C Inhibitors in the Treatment of Non–Small Cell Lung Cancer (2007) (0)
Abstract B04: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. (2014) (0)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers (2018) (0)
Pemetrexed Equivalent to Docetaxel for Recurrent NSCLC Patients (2003) (0)
ASCO Updates Patient Guidelines (2005) (0)
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy (2019) (0)
Phase I Trials Today (2015) (0)
Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). (2022) (0)
TheMouseAlbumin Enhancer Contains aNegative Regulatory Element ThatInteracts withaNovelDNA-Binding Protein (1990) (0)
Research access: The views of prospective research participants: (523652012-024) (2013) (0)
P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC (2007) (0)
Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer (2019) (0)
Phase III trial of gefitinib versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (2007) (0)
I-95. Targeting the EGFR: Prognostic and clinical implications (2003) (0)
EGFRMutations in Non – Small-Cell Lung Cancer Find , Divide , and Conquer (2015) (0)
Targeted Therapy Against All Three VEGF Receptors by Cediranib Enhances the Antitumor and Anti-metastatic Effects of Paclitaxel and Radiation in an Orthotopic Human Lung Cancer Model (2010) (0)
60 Gy Standard Radiotherapy for NSCLC Challenged (2005) (0)
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development (2014) (0)
P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab: Topic: Biomarkers (2017) (0)
The anti-vascular and anti-tumor response of human lung cancer growing orthotopically in mice to AEE788, a tyrosine kinase inhibitor of EGFR and VEGFR, is dependent upon EGF/TGFα expression (2005) (0)
Bevacizumab in non-small cell lung cancer. Discussion (2007) (0)
Targeted Therapy in Solid Tumors: Lung Cancer (2015) (0)
Gemcitabine Regimens Significantly Improve Advanced NSCLC (2003) (0)
P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT (2016) (0)
P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC (2018) (0)
PD-083 Pemetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials (2005) (0)
PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer. (2022) (0)
Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells (2012) (0)
Abstract 1397: VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer model (2010) (0)
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial. (2022) (0)
Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (2020) (0)
P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection (2017) (0)
Abstract B096: Responding to stakeholder needs for cancer screening and prevention: Using formative evaluation to tailor outreach and navigation programming in Connecticut (2020) (0)
Novel Apoptosis-Inducing Agents Entering Phase I Trials (2003) (0)
Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors (2002) (0)
Second-Generation Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer (2007) (0)
Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors (2007) (0)
ES06.01 Recent Advances in Second Line Treatment (2019) (0)
P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy (2017) (0)
P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Topic: IT Biomarkers (2017) (0)
FDA Approves Alimta/Cisplatin for Malignant Pleural Mesothelioma (2005) (0)
Adjuvant Treatment Yields Survival Benefit in Early-Stage NSCLC (2005) (0)
Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell lung cancer: A5-02 (2007) (0)
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC (2022) (0)
Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer (2022) (0)
Abstract 4382: Genome-Wide Gene Expression analysis and molecular portraits regulated by NASEp, an inhibitor of CREB and CBP interaction, in non-small cell lung cancer. (2013) (0)
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A). (2021) (0)
Financial Constraints to Molecular Biomarker Testing (2018) (0)
Tumor Cavitation Is Associated With Epidermal Growth Factor Expression and Is a Predictor of Poor Outcome in Patients With Stage I Non-Small Cell Lung Cancer (2003) (0)
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities (2022) (0)
PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection: Topic: Medical Oncology (2017) (0)
Cetuximab Improves Efficacy of Cisplatin/Vinorelbine in EGFR-Positive NSCLC Patients (2005) (0)
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008 (2008) (0)
EGFR expression and the flexibility of FLEX. (2012) (0)
AACR Celebrates 50 Years of Tobacco Research and Policy (2014) (0)
Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance (2021) (0)
Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation Therapy (2010) (0)
The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center (2019) (0)
Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. (2009) (0)
Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models (2011) (0)
Abstract PO-078: Exploring adversarial image attacks on deep learning models in oncology (2021) (0)
Future Directions in the Management of Non-Small Cell Lung Cancer Harboring Driver Mutations. (2022) (0)
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS (2011) (0)
1 JAK 1 / STAT 3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer (2017) (0)
New Targeted Therapies: Recognizing and Managing Toxicities (2003) (0)
P-762 Limited small cell lung cancer (LSCLC) — observations from the National Cancer Database on the impact of age, gender and treatment on survival (2005) (0)
Gated 4D PET/CT: Improving Radiation Treatment Planning for Patients With Lung Cancer (2005) (0)
Targeting key pathways in tumour growth and development (2005) (0)
Navigating the CMS 14-Day Rule in Biomarker Testing (2018) (0)
SS-5 Novel therapy for Advanced Non-Small Cell Lung Cancer(NSCLC) (2001) (0)
Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer (2019) (0)
Abstract 3334: CREB is required forKRAS-driven lung tumorigenesis (2018) (0)
Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target (2010) (0)
Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC) (2022) (0)
O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib (2005) (0)
Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling. (2021) (0)
EGFR-TK Mutations Underlie Majority of Responses to Gefitinib (2005) (0)
Interobserver a nd I ntraobserver V ariability i n M easurement of N on-Small-Cell C arcinoma L ung L esions: Implications f or A ssessment o f T umor R esponse (2003) (0)
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). (2023) (0)
Abstract 3435: VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer model (2010) (0)
From the Guest Editors: Progress and Future Directions for the Treatment of Advanced Lung Cancer. (2015) (0)
FDA Approves Tarceva in Second-Line Tx (2005) (0)
Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities (2015) (0)
Surgery After CT/RT in NSCLC: Benefits Upheld With Longer Follow-up of Intergroup 0139 (2003) (0)
MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas (2017) (0)
L4.1 Evolution of Battle Trials at Md Anderson Cancer Center (2012) (0)
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A (2014) (0)
P-518 Asian ethnicity as a predictor of response to gefitinib in non-small cell lung cancer (2005) (0)
Abstract 1144: Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis (2016) (0)
Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells . (2013) (0)
On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer (2021) (0)
2007 Highlights from: the 12th World Conference on Lung Cancer Seoul, South Korea; September 2-6, 2007 (2007) (0)
159 Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel (2004) (0)
P-969 The level of EGFR phosphorylation in NSCLC core biopsies fromin situ tumor prior to vessel ligation may be more accurate than tissue obtained immediately after lobectomy (2005) (0)
BATTLE (Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination) (2008) (0)
Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009 (2009) (0)
Chapter 47 – Phase 1 Trials Today (2008) (0)
Comprar Antiangiogenic Cancer Therapy | James L. Abbruzzese | 9780849327995 | Informa Healthcare (2007) (0)
2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006 (2007) (0)
Question-and-Answer Forum (2005) (0)
Abstract 2094: GSK-3 is a novel target of CREB and GSK-3-CREB signaling participates in cell survival in lung cancer (2015) (0)
Abstract 2878: Targeting the CXCL5-CXCR2-CREB signaling axis suppresses growth, survival, and invasion of lung adenocarcinoma. (2013) (0)
Targeted therapy against VEGFR tyrosine kinase signaling by vandetanib inhibits tumor growth, angiogenesis, and progression in orthotopic human small cell lung cancer models (2008) (0)
Larotrectinib in NTRK -Rearranged Solid Tumors (2020) (0)
MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400) (2021) (0)
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities) (2009) (0)
Identifying and Solving Top Challenges to Oncology Biomarker Testing (2018) (0)
Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems? (2020) (0)
Abstract S12-06: Social Determinants of Health (SDOH) barriers as predictors of intent to vaccinate for COVID-19 in a vulnerable population (2021) (0)
Spiral CT Scanning Finds Very Early Lung Cancers, ELCAP Data Show (2005) (0)
Erratum: Molecular targeted therapy for lung cancer (Lancet (2005) 266 (1507-1508)) (2005) (0)
C1-02: Randomized Phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as 1st-line treatment for advanced NSCLC (2007) (0)
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. (2023) (0)
Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort. (2016) (0)
Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer (2023) (0)
Early Intervention With Epoetin Prevents Anemia in NSCLC Patients (2003) (0)
29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC) (2022) (0)
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. (2012) (0)
Clinical significance of TILs subtypes in non-small cell lung cancer. (2014) (0)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. (2017) (0)
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status (2021) (0)
635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (2022) (0)
Department of Error (2005) (0)
Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC (2020) (0)
E2F8 and its target genes as novel therapeutic targets for lung cancer (2016) (0)
Erlotinib Prolongs Survival in Never Smokers, Subgroup Analysis Shows (2005) (0)
A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. (2022) (0)

This paper list is powered by the following services:

Roy S. Herbst

Roy S. Herbst's AcademicInfluence.com Rankings

Why Is Roy S. Herbst Influential?

Roy S. Herbst's Published Works

Published Works

Other Resources About Roy S. Herbst